Dr. Kristina Janjetović

Kristina Janjetović has finished her PhD thesys "The effect of metformin on the apoptosis of glioma and melanoma cells in vitro and on melanoma growth in vivo" in 2014 at the Faculty of Medicine, University of Belgrade. She graduated in 2002, at the Faculty of Biology at the University of Belgrade in Molecular Biology and Physiology. Dr. Kristina Janjetović studies new approaches in tumor therapy: molecular and cellular mechanisms underlying the cytotoxic effect of new antitumor compounds in vitro and the role of autophagy and its modulation in different pathologies. She was on scientific specialization from 2003 to 2005 at the Institute of Pathophysiology, Medical University of Innsbruck, and during her training in Austria, in 2004, she received an award from the Osterreichische Krebshilfe for research funding "The role of the tumor suppressor PTEN in the development of leukemias and apoptosis of leukemias induced by glucocorticoids" and in 2005 for the research "Functional analysis of new candidate genes selected from comparative profiling of lymphoblasts in children with acute lymphoblastic leukemia". The doctoral dissertation of Dr. Marina Stamenković, whose candidate was a commentor, was awarded with "Goran Ljubijankić Foundation" in 2021. From 2019-2021 she was the project leader "Molecular mechanisms of action of pantoprazole on the induction of apoptosis and/or autophagy in non-small cell lung cancer (NSCLC) in vitro", funded by the Phillip Morris company as part of the "Start up for Science" program. From 2021-2023. she was responsible for project tasks: "The role of pantoprazole, a proton pump inhibitor, in the regulation of autophagy and apoptosis in the NSCLC H460 cell line" and "Establishment of a methodology for the transfection of the human neuroblastoma cell line SHSY-5Y with plasmids carrying mutations in the amyloid-β protein precursor gene (Swedish ,751, wild-type), as an in vitro model of Alzheimer's disease".